ReviewBreast cancer (Dove Medical Press)2025
Mechanisms and Management of Albumin-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.
Review in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy.Journal of proteome research · 2026Article
- Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Research on paclitaxel in chemotherapy-induced neuropathic pain: a bibliometric analysis integrating multiple databases.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer incidence continues to rise globally, with molecular subtyping now playing a critical role in prognosis and treatment selection. The main subtypes-Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancer (TNBC)-exhibit distinct clinical behaviors and treatment responses, with respective molecular characteristics. Chemotherapy plays a pivotal role in the comprehensive treatment of breast cancer, being widely used in neoadjuvant, adjuvant, and metastatic systemic therapy. Albumin-Paclitaxel based regimens remain the cornerstone of clinical treatment, particularly for highly aggressive subtypes like triple-negative breast cancer (TNBC) and HER2-positive breast cancer. However, 30-60% of breast cancer patients receiving chemotherapy develop chemotherapy-induced peripheral neuropathy (CIPN). Approximately 35% experience severe (≥grade 2) symptoms, often requiring dose modification or treatment discontinuation. Albumin-Paclitaxel's neurotoxicity primarily involves two mechanisms: microtubule stabilization disruption causing axonal transport impairment, and sensory neuron mitochondrial dysfunction. For younger patients, this presents dual clinical challenges: controlling tumor progression while managing neuropathic pain and functional impairment that significantly affect quality of life and work capacity. Treatments are constantly evolving and currently, the most effective treatments (eg duloxetine, cold therapy). Understanding CIPN pathogenesis, diagnostic approaches, and developing effective prevention/treatment strategies is clinically crucial. This maintains treatment adherence and efficacy while improving long-term quality of life for breast cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.